Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/04/2020.
Displaying: 645 trials in your specialties ()
View trials across your selected specialties

The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Biliary Tract Cancer
View Full Trial
INTERVENTION

Drug: Nab-paclitaxel,S-1

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College, Beijing, China

Brief Summary

Advanced biliary tract adenocarcinoma has a poor prognosis with limited therapeutic options. Nab-paclitaxel plus S-1 chemotherapy will be given to untreated patients with advanced biliary tract adenocarcinoma for the first-line treatment.

Nab-Paclitaxel and Durvalumab With or Without Neoantigen Vaccine in Treating Patients With Metastatic Triple Negative Breast Cancer

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Prognostic Stage IV Breast Cancer AJCC v8, Progesterone Receptor ...
View Full Trial
INTERVENTION

Drug: Poly ICLC, Drug: Carboplatin, Biological: Durvalumab, Drug: Gemcitabine Hydrochloride, Drug: Nab-paclitaxel, Biological: Personalized Synthetic Long Peptide Vaccine

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

This phase II trial studies how well nab-paclitaxel and durvalumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) work in treating participants with triple negative breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel and durvalumab with or without neoantigen vaccine will work better in treating participants with triple negative breast cancer.

Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Pancreatic Neoplasms (Locally Advanced Non-metastatic)
View Full Trial
INTERVENTION

Drug: nab-paclitaxel, Radiation: 60Gy in 30#, Radiation: 50.4Gy in 28#, Drug: Nelfinavir, Drug: Capecitabine, Drug: Gemcitabine

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Oxford University Hospitals, Churchill Cancer Centre, Headington, Oxfordshire, United Kingdom

Brief Summary

This study will evaluate the role of increasing radiotherapy dose and addition of nelfinavir to chemoradiotherapy (CRT) in patients with inoperable pancreatic cancer that has not spread beyond the pancreas. Currently in the United Kingdom (UK), either chemotherapy alone or chemotherapy followed by CRT can be used in the management of inoperable pancreatic cancer that has not spread. CRT consists of 25-30 radiotherapy treatments in combination with chemotherapy. Although this treatment is effective in controlling local symptoms and slowing down the pace of cancer, in most cases it is unable to shrink it enough to make it operable. Some of the reasons for this could be the lack of oxygen and lack of blood flow within the tumour making it resistant to the effects of CRT. This study will investigate whether increasing the dose of radiotherapy, or increasing the oxygen and blood supply to the tumour by giving nelfinavir, or a combination of both, can improve outcomes. We also want to know what the additional toxicities from such intensive approaches are. All participants will initially receive 12 weeks of chemotherapy, and those with stable or responding disease will receive further study treatment. The treatment allocation to 1 of the 5 options outlined below will be done at random by computer and neither the doctor nor the patient can choose the treatment option. The process of randomisation ensures that all treatment arms are equally balanced in terms of patient and tumour characteristics, and to reduce the possibility of bias. The study will consist of 2 stages. In the 1st stage we aim to find the right dose of nelfinavir to combine with CRT, and this will require around 27 participants of whom up to 18 will receive nelfinavir together with CRT. In the 2nd stage, we want to find out the benefits of this approach over and above standard treatments and therefore we will recruit the order of 262 participants and allocate 170 to 1 of the 5 following treatment arms: Arm A: Nelfinavir together with CRT Arm B: CRT (without nelfinavir) Arm C: Nelfinavir together with CRT (but using a higher than conventional dose of radiotherapy) Arm D: CRT without nelfinavir (but using a higher than conventional dose of radiotherapy) Arm E: Chemotherapy alone (without radiotherapy) Participants who are ineligible or refuse randomisation will be treated as per local standard but will remain in the study for follow up at 26, 39 and 52 weeks. Their data will contribute to an Overall Survival (OS) analysis.

Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Cancer
View Full Trial
INTERVENTION

Drug: nanoparticle albumin-bound paclitaxel, Drug: S1, Drug: Gemcitabine

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Peking University Cancer Hospital and Institute, Beijing, Beijing, China

Brief Summary

This is a randomized phase II trial comparing the first-line treatment with nab-paclitaxel plus S-1(AS) and nab-paclitaxel plus gemcitabine(AG) in advanced pancreatic ductal adenocarcinoma (PDA) with primary tumor nonexcision in Chinese patients.

Neoadjuvant Therapy Followed by Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Pancreas Cancer
View Full Trial
INTERVENTION

Drug: FOLFIRINOX Drugs, Drug: Gemcitabine-nab Paclitaxel

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

Brief Summary

The purpose of this study is to evaluate a new treatment routine for patients with borderline resectable and unresectable pancreas cancers.

Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Neoplasms
View Full Trial
INTERVENTION

Drug: Chemotherapy, Radiation: Stereotactic radiotherapy, Procedure: Surgery

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Centre Francois Baclesse, Esch-sur-Alzette, SUD, Luxembourg

Brief Summary

The goal of the present study is to test if in situations of borderline resectable patients a neoadjuvant treatment combining Gemzar-Abraxane and stereotactic radiosurgery could increase the median OS rates above 30 months that means at least 12 months more than the 18-20 months generally described.

Phase IIb Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Cancer
View Full Trial
INTERVENTION

Drug: ATRA, Drug: Gemcitabine, Drug: nab-paclitaxel

Eligibility
  • Ages: 16 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

This is an open-label, multi-centre, randomised, stratified, phase IIb clinical trial of ATRA administered in combination with gemcitabine and nab-paclitaxel in patients with laPDAC.

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    mCRC, Colorectal Cancer Metastatic
View Full Trial
INTERVENTION

Biological: Aldoxorubicin Hydrochloride, Biological: ALT-803, Biological: ETBX-011, Biological: ETBX-021, Biological: ETBX-051, Biological: ETBX-061, Biological: GI-4000, Biological: GI-6207, Biological: GI-6301, Biological: haNK, Drug: Avelumab, Drug: Capecitabine, Drug: Cetuximab, Drug: Cyclophosphamide, Drug: 5-Fluorouracil, Drug: Leucovorin, Drug: Nab-paclitaxel, Drug: Oxaliplatin, Drug: Regorafenib, Procedure: SBRT

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Brief Summary

QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: Phase 1b/2 NANT CRC Vaccine vs Regorafenib in Subjects with CRC Who have Previously Treated with SOC.

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
View Full Trial
INTERVENTION

Drug: siG12D-LODER, Drug: Gemcitabine+nab-Paclitaxel

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Rambam Medical Center, Haifa, Israel

Brief Summary

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - Progression-free survival (PFS) in the study population.

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma o...
View Full Trial
INTERVENTION

Drug: Nivolumab, Drug: nab-paclitaxel

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

St. Elizabeth's Healthcare, Edgewood, Kentucky, United States

Brief Summary

The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need despite recent clinical research progress. Early progression for a subset of NSCLC patients receiving nivolumab is a specific area of clinical need.